In this leadership position within Global Medical Affairs, the individual will establish and drive the overarching scientific communication strategy, publication planning, and medical information infrastructure supporting the immunology pipeline, including lead programs such as obexelimab and orelabrutinib across indications including IgG4-Related Disease (IgG4-RD), Systemic Lupus Erythematosus (SLE), and Multiple Sclerosis (MS). Zenas' earlier stage programs include ZB021, a clinical-stage, potentially best-in-class, oral, IL-17AA/AF inhibitor; ZB022, a preclinical, potentially best-in-class, oral, brain-penetrant, TYK2 inhibitor; and ZB014, a preclinical half-life extended anti-CD-19 and FcRIIb monoclonal antibody.